I

Inno-Gene SA
WSE:IGN

Watchlist Manager
Inno-Gene SA
WSE:IGN
Watchlist
Price: 5.04 PLN -0.4% Market Closed
Market Cap: 17.7m PLN
Have any thoughts about
Inno-Gene SA?
Write Note

Inno-Gene SA
Net Issuance of Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Inno-Gene SA
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
I
Inno-Gene SA
WSE:IGN
Net Issuance of Debt
-zł105k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Medicofarma Biotech SA
WSE:MDB
Net Issuance of Debt
zł596.7k
CAGR 3-Years
37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
R
Ryvu Therapeutics SA
WSE:RVU
Net Issuance of Debt
zł93.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Selvita SA
WSE:SLV
Net Issuance of Debt
-zł38.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Inno-Gene SA
Glance View

Market Cap
17.7m PLN
Industry
Life Sciences Tools & Services

Inno Gene SA engages in the management of startup biotechnology companies. The company is headquartered in Poznan, Woj. Wielkopolskie. The company went IPO on 2011-02-08. Inno-Gene SA’s portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.

IGN Intrinsic Value
2.03 PLN
Overvaluation 60%
Intrinsic Value
Price
I

See Also

What is Inno-Gene SA's Net Issuance of Debt?
Net Issuance of Debt
-105k PLN

Based on the financial report for Jun 30, 2024, Inno-Gene SA's Net Issuance of Debt amounts to -105k PLN.

Back to Top